This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

MEDTRONIC CLASS ACTION ALERT: Levi & Korsinsky Notifies Investors With Losses On Investment In Medtronic, Inc. Of Class Action Lawsuit And Upcoming Deadline Of August 26, 2013 To Seek Lead Plaintiff Position

NEW YORK, Aug. 14, 2013 /PRNewswire/ -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the USDC for the District of Minnesota on behalf of investors who purchased Medtronic, Inc. ("Medtronic" or the "Company") (NYSE: MDT) stock between December 8, 2010 and August 3, 2011.

(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO )

For more information, click here: http://zlk.9nl.com/medtronic-mdt/ .  

The complaint alleges that defendants violated federal securities laws by issuing materially false and misleading statements concerning the use of the Company's INFUSE Bone Graft ("Infuse") product for the reduction of complications and pain associated with degenerative disc disease. On June 23, 2011, Medtronic issued a press release acknowledging that the U.S. Senate had requested information regarding Infuse. Then on June 28, 2011, an issue of The Spine Journal identified conflicts of interest concerning the researchers who had performed studies on Infuse. On August 3, 2011, Medtronic announced it would release Infuse data to the public and agreed to pay $2.5 million to Yale University so that researchers might conduct a review of previous studies. According to the complaint, the true facts, which defendants concealed from the investing public during the class period, included that the Company had engaged in a scheme with certain researchers to downplay the risks and side effects associated with Infuse and that once those risks were fully appreciated by surgeons, use of the product would drop significantly. 

If you suffered a loss in Medtronic you have until August 26, 2013 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (877) 363-5972, or visit http://zlk.9nl.com/medtronic-mdt/.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington D.C.  The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits.  Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:     Levi & Korsinsky, LLP Joseph Levi, Esq. Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor  New York, NY 10004 Tel: (212) 363-7500 Toll Free:  (877) 363-5972 Fax: (866) 367-6510 www.zlk.com

SOURCE Levi & Korsinsky, LLP

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,135.05 +103.91 0.61%
S&P 500 1,999.42 +15.29 0.77%
NASDAQ 4,553.8170 +34.9150 0.77%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs